Immune monitoring of DC vaccinated advanced melanoma patients
Post-clinical protocol
IFNgamma ELISPOT of peptide pulsed, leukapheresis derived PBMC
Tumor antigen specific activation of CD8 and CD4 DTH infiltrating T cells (CD137, CD107a, CD154, cytokines TNFalpha and IFNgamma)
Protocol Steps:
- biomaterial type
- CD107a receptor,
- T cell,
- CD8,
- CD137 receptor,
- CD154 receptor,
- Peripheral Blood Mononuclear Cell,
- Tumor necrosis factor alpha,
- Interferon gamma,
- CD4
created over 16 years ago (2 March 2009) last modified over 13 years ago (28 September 2011)  [ RDF ]  [ RelFinder ]